Literature DB >> 11389873

Major roles of prostanoid receptors IP and EP(3) in endotoxin-induced enhancement of pain perception.

A Ueno1, H Matsumoto, H Naraba, Y Ikeda, F Ushikubi, T Matsuoka, S Narumiya, Y Sugimoto, A Ichikawa, S Oh-ishi.   

Abstract

To know the roles of prostaglandin I (IP) and prostaglandin E (EP) receptors in pain perception, we compared the acetic acid-induced writhing response in mice deficient in prostaglandin receptors, i.e. IP, EP(1,) EP(2,) EP(3,) or EP(4,) with or without lipopolysaccharide (LPS) pretreatment. Without LPS pretreatment, IP-receptor deficient mice showed a significantly smaller number of responses, as previously reported, whereas mice deficient in any of the EP-receptor subtypes showed a number of writhings similar to those of wild-type mice. When mice were pretreated with LPS for 24 hr to induce cyclooxygenase-2 expression, the wild-type as well as EP(1)-, EP(2)-, or EP(4)-receptor-deficient mice showed a similar enhanced writhing response, whereas IP- and EP(3)-receptor-deficient mice had a significantly less enhanced number of writhings. These results indicate that IP and EP(3) are the major prostaglandin receptors mediating the enhanced acetic acid-induced writhing response in mice pre-exposed to LPS, i.e. in endotoxin-enhanced inflammatory nociception.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389873     DOI: 10.1016/s0006-2952(01)00654-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Prostaglandin E2 Upregulated Trigeminal Ganglionic Sodium Channel 1.7 Involving Temporomandibular Joint Inflammatory Pain in Rats.

Authors:  Peng Zhang; Ye-Hua Gan
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

Review 2.  Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs.

Authors:  Noritaka Kawada; Toshiki Moriyama; Harumi Kitamura; Ryohei Yamamoto; Yoshiyuki Furumatsu; Isao Matsui; Yoshitsugu Takabatake; Yasuyuki Nagasawa; Enyu Imai; Christopher S Wilcox; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

3.  RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists.

Authors:  Keith R Bley; Anindya Bhattacharya; Don V Daniels; Joel Gever; Alam Jahangir; Counde O'Yang; Steven Smith; Dinesh Srinivasan; Anthony P D W Ford; Mary-Frances Jett
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  Prostanoids and inflammation: a new concept arising from receptor knockout mice.

Authors:  Shuh Narumiya
Journal:  J Mol Med (Berl)       Date:  2009-07-17       Impact factor: 4.599

Review 5.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

Review 6.  Neural circuitry engaged by prostaglandins during the sickness syndrome.

Authors:  Clifford B Saper; Andrej A Romanovsky; Thomas E Scammell
Journal:  Nat Neurosci       Date:  2012-07-26       Impact factor: 24.884

7.  Prostanoid Receptor Subtypes and Its Endogenous Ligands with Processing Enzymes within Various Types of Inflammatory Joint Diseases.

Authors:  Mohammed A Al-Madol; Mohammed Shaqura; Thilo John; Rudolf Likar; Reham Said Ebied; Magdi M Salih; Sascha Treskatsch; Michael Schäfer; Shaaban A Mousa
Journal:  Mediators Inflamm       Date:  2020-11-12       Impact factor: 4.711

8.  Abnormal Expression of Prostaglandins E2 and F2α Receptors and Transporters in Patients with Endometriosis.

Authors:  Halima Rakhila; Nathalie Bourcier; Ali Akoum; Marc Pouliot
Journal:  Biomed Res Int       Date:  2015-07-09       Impact factor: 3.411

Review 9.  Physiology and pathophysiology of prostanoid receptors.

Authors:  Shuh Narumiya
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2007-12       Impact factor: 3.493

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.